

STEMCELLS INC  
Form DEFA14A  
August 16, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **August 16, 2016**

**StemCells, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**39899 Balentine Drive, Suite 200, Newark, California**  
**(Address of principal executive offices)**

Registrant's telephone number, including area code: **(650) 670-2282**

**000-19871**  
**(Commission**

**File Number)**

**94-3078125**  
**(I.R.S. Employer**

**Identification No.)**

**94560**  
**(Zip Code)**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On August 16, 2016, StemCells, Inc., a Delaware corporation, issued a press release announcing its entry into an Agreement and Plan of Merger and Reorganization with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel and C&RD Israel Ltd., an Israeli corporation and wholly-owned subsidiary of the Company. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated August 16, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

August 16, 2016

**StemCells, Inc.**

/s/ Kenneth B. Stratton  
Name: Kenneth B. Stratton  
Title: President

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated August 16, 2016